Assessment of ocrelizumab impact on neurofilament levels in multiple sclerosis patients

1 Maier S, Barcutean L, Andone S, Manu D, Sarmasan E. Bajko Z, et al. Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis. Int J Mol Sci. 2023;24(5):4375. DOI: 10.3390/ijms24054375 Search in Google Scholar

2 Dutta R, Trapp BD. Relapsing and Progressive Forms of Multiple Sclerosis: Insights from Pathology. Curr Opin Neurol. 2014;27(3):271-278. DOI: 10.1097/WCO.0000000000000094 Search in Google Scholar

3 Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the Clinical Course of Multiple Sclerosis: The 2013 Revisions. Neurology. 2014;83(3):278-286. DOI: 10.1212/WNL.0000000000000560 Search in Google Scholar

4 Ebers GC. Natural History of Primary Progressive Multiple Sclerosis. Mult Scler. 2004;10(suppl 1):S8-S13. DOI: 10.1177/135245850401000103 Search in Google Scholar

5 Syed YY. Ocrelizumab: A Review in Multiple Sclerosis. CNS Drugs. 2018;32(9):883-890. DOI: 10.1007/s40263-018-0568-7 Search in Google Scholar

6 Maier S, Motataianu A, Barcutean L, Balint A, Hutanu A, Bajko Z, et al.; Balasa, R. Interferon-β 1a, an Immunomodulator in Relapsing-Remitting Multiple Sclerosis Patients. The Effect on Pro-inflammatory Cytokines. Farmacia. 2020;68(1):65-75. DOI: 10.31925/farmacia.2020.1.10 Search in Google Scholar

7 Michel L, Touil H, Pikor NB, Gommerman JL, Prat A, Bar-Or A. B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammation. Front Immunol, 2015;6:636. DOI: 10.3389/fimmu.2015.00636 Search in Google Scholar

8 Lamb YN. Ocrelizumab: A Review in Multiple Sclerosis. Drugs. 2022;82:323-334. DOI: 10.1007/s40265-022-01672-9 Search in Google Scholar

9 Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D. et al. ECTRIMS/EAN Guideline on the Pharmacological Treatment of People with Multiple Sclerosis. Mult Scler J. 2018;24(2):96-120. DOI: 10.1177/1352458517751049 Search in Google Scholar

10 Klineova S, Lublin FD. Clinical Course of Multiple Sclerosis. Cold Spring Harb Perspect Med. 2018;8(9):a028928. DOI: 10.1101/cshperspect.a028928 Search in Google Scholar

11 Compston A, Coles A. Multiple Sclerosis. Lancet. 2008;372:1502-1517. doi.org/10.1016/S0140-6736(08)61620-7 DOI: 10.1016/S0140-6736(08)61620-7 Search in Google Scholar

12 Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D, University of British Columbia MS Clinic Neurologists. Early Onset Multiple Sclerosis: A Longitudinal Study. Neurology. 2002;59:1006-1010. DOI: 10.1212/WNL.59.7.1006 Search in Google Scholar

13 Lassmann H, Bruck W, Lucchinetti CF. The Immunopathology of Multiple Sclerosis: An Overview. Brain Pathol. 2007;17(2):210-218. DOI: 10.1111/j.1750-3639.2007.00064.x Search in Google Scholar

14 Ransohoff RM, Hafler DA, Lucchinetti CF. Multiple Sclerosis-A Quiet Revolution. Nat Rev Neurol. 2015;11(3):134-142. DOI: 10.1038/nrneurol.2015.14 Search in Google Scholar

15 Balasa R, Maier S, Barcutean L, Stoian A, Motataianu A. The Direct Deleterious Effect of Th17 Cells in the Nervous System Compartment in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: One Possible Link between Neuroinflammation and Neurodegeneration. Rev Romana Med Lab. 2020;28(1):9-17. DOI: 10.2478/rrlm-2020-0005 Search in Google Scholar

16 Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Eng J Med. 2017;376(3):221-234. DOI: 10.1056/NEJMoa1601277 Search in Google Scholar

17 Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017;376(3):209-220. DOI: 10.1056/NEJMoa1606468 Search in Google Scholar

18 Margoni M, Preziosa P, Tortorella P, Filippi M, Rocca MA. Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers. Neurotherapeutics. 2022;19(4):1216-1228. DOI: 10.1007/s13311-022-01252-5 Search in Google Scholar

19 Cross A, Bennett J, von Büdingen HC, Carruthers R, Edwards K, Fallis R, et al. Ocrelizumab Treatment Reduced Levels of Neurofilament Light Chain and Numbers of B Cells in the Cerebrospinal Fluid of Patients with Relapsing Multiple Sclerosis in the OBOE Study (S56.008). Neurology. 2019;92(suppl 15):S56.008. DOI: 10.1212/WNL.92.15_supplement.S56.008. DOI: 10.1212/WNL.92.15_supplement.S56.008 Search in Google Scholar

20 Elliott C, Belachew S, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, et al. Chronic White Matter Lesion Activity Predicts Clinical Progression in Primary Progressive Multiple Sclerosis. Brain. 2019;142(9):2787-2799. DOI: 10.1093/brain/awz212 Search in Google Scholar

21 Ferreira-Atuesta C, Reyes S, Giovanonni G, Gnanapavan S. The Evolution of Neurofilament Light Chain in Multiple Sclerosis. Front Neurosci. 2021;15:642384. DOI: 10.3389/fnins.2021.642384 Search in Google Scholar

22 Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament Light Chain as a Biomarker in Neurological Disorders. J. Neurol. Neurosurg. Psychiatry. 2019;90(8):870-881. DOI: 10.1136/jnnp-2018-320106 Search in Google Scholar

23 Gnanapavan S, Giovannoni G. Developing Biomarkers for MS. Curr Top Behav Neurosci. 2015;26:179-194. DOI: 10.1007/7854_2014_362 Search in Google Scholar

24 Gunnarsson M, Malmeström C, Axelsson M, Sundström P, Dahle C, Vrethem M, et al. Axonal Damage in Relapsing Multiple Sclerosis Is Markedly Reduced by Natalizumab. Ann Neurol. 2011;69(1):83-89. DOI: 10.1002/ana.22247 Search in Google Scholar

25 Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of Multiple Sclerosis: 2017 Revisions of the McDonald Criteria. The Lancet Neurol. 2018;17(2):162-173. DOI: 10.1016/S1474-4422(17)30470-2 Search in Google Scholar

26 Kurtzke JF. Rating Neurologic Impairment in Multiple Sclerosis: An Expanded Disability Status Scale (EDSS). Neurology. 1983;33(11):1444-1452. DOI: 10.1212/WNL.33.11.1444 Search in Google Scholar

27 Paul A, Comabella M, Gandhi R. Biomarkers in Multiple Sclerosis. Cold Spring Harb Perspect Med. 2019;9(3):a029058. DOI: 10.1101/cshperspect.a029058 Search in Google Scholar

28 Bărcuţean LI, Romaniuc A, Maier S, Bajko Z, Moţăţăianu A.; Hutanu A et al. Clinical and Serological Biomarkers of Treatment’s Response in Multiple Sclerosis Patients Treated Continuously with Interferonβ-1b for More than a Decade. CNS Neurol. Disord. Drug Targets. 2018;17(10):780-792. DOI: 10.2174/18715273176 66180917095256 Search in Google Scholar

29 Balasa R, Maier S, Voidazan S, Hutanu A, Bajko Z, Motataianu A, et al. Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response. CNS Neurol. Disord. Drug Targets. 2017;16(1):93-101. DOI: 10.2174/1871527315666 160615110739 Search in Google Scholar

30 Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal Transection in the Lesions of Multiple Sclerosis. N Engl J Med. 1998;338(5):278-285. DOI: 10.1056/NEJM199801293380502 Search in Google Scholar

31 De Stefano N, Narayanan S, Francis SJ, Smith S, Mortilla M, Carmela Tartaglia M, et al. Diffuse Axonal and Tissue Injury in Patients with Multiple Sclerosis with Low Cerebral Lesion Load and No Disability. Arch Neurol. 2002;59(10):1565-1571. DOI: 10.1001/archneur.59.10.1565 Search in Google Scholar

32 Filippi M, Bozzali M, Rovaris M, Gonen O, Kesavadas C, Ghezzi A.; et al. Evidence for Widespread Axonal Damage at the Earliest Clinical Stage of Multiple Sclerosis. Brain. 2003;126(Pt2):433-437. DOI: 10.1093/brain/awg038 Search in Google Scholar

33 Gaetani L, Eusebi P, Mancini A, Gentili L, Borrelli A, Parnetti L, et al. Cerebrospinal Fluid Neurofilament Light Chain Predicts Disease Activity after the First Demyelinating Event Suggestive of Multiple Sclerosis. Mult Scler Relat Disord. 2019;35:228-232. DOI: 10.1016/j.msard.2019.07.025 Search in Google Scholar

34 Domingues RB, Fernandes GBP, Leite FBVDM, Senne C. Neurofilament Light Chain in the Assessment of Patients with Multiple Sclerosis. Arq. Neuropsiquiatr. 2019;77(6):436-441. DOI: 10.1590/0004-282x20190060 Search in Google Scholar

35 Bar-Or A, Thanei GA, Harp C, Bernasconi C, Bonati U, Cross AH, et al. Blood Neurofilament Light Levels Predict Non-relapsing Progression Following Anti-CD20 Therapy in Relapsing and Primary Progressive Multiple Sclerosis: Findings from the Ocrelizumab Randomised, Double-blind Phase 3 Clinical Trials. EbioMedicine. 2023;93:104662. DOI: 10.1016/j.ebiom.2023.104662 Search in Google Scholar

36 Abbadessa G, Miele G, Maida E, Vanore E, Cipriano L, Coppola C, et al. Immunomodulatory Effects of Ocrelizumab and Candidate Biomarkers for Monitoring Treatment Response in Multiple Sclerosis. Mult Scler. 2023;29(7):779-788. DOI: 10.1177/13524585221147635 Search in Google Scholar

37 Romme Christensen J, Komori M, von Essen MR, Ratzer R, Börnsen L, Bielekova B, et al. CSF Inflammatory Biomarkers Responsive to Treatment in Progressive Multiple Sclerosis Capture Residual Inflammation Associated with Axonal Damage. Mult Scler. 2019; 25(7):937-946. DOI: 10.1177/1352458518774880 Search in Google Scholar

38 Thebault S, Bose G, Booth R, Freedman MS. Serum Neurofilament Light in MS: The First True Blood-based Biomarker? Mult Scler. 2022;28(10):1491-1497. DOI: 10.1177/1352458521993066 Search in Google Scholar

39 Kuhle J, Barro C, Disanto G, Mathias A, Soneson C, Bonnier G, et al. Serum Neurofilament Light Chain in Early Relapsing Remitting MS Is Increased and Correlates with CSF Levels and with MRI Measures of Disease Severity. Mult Scler. 2016;22(12):1550-1559. DOI: 10.1177/1352458515623365 Search in Google Scholar

40 Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius A, et al. Comparison of Three Analytical Platforms for Quantification of the Neurofilament Light Chain in Blood Samples: ELISA, Electrochemiluminescence Immunoassay and Simoa. Clin Chem Lab Med. 2016;54(10):1655-1661. DOI: 10.1515/cclm-2015-1195 Search in Google Scholar

41 Mathias A, Pantazou V, Perriot S, Canales M, Jones S, Oberholster L, et al. Ocrelizumab Impairs the Phenotype and Function of Memory CD8+ T Cells: A 1-Year Longitudinal Study in Patients With Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023;10(2):e200084. DOI: 10.1212/NXI.0000000000200084 Search in Google Scholar

42 Turner B, Cree BAC, Kappos L, Montalban X, Papeix C, Wolinsky JS, et al. Ocrelizumab Efficacy in Subgroups of Patients with Relapsing Multiple Sclerosis. J Neurol. 2019;266(5):1182-1193. DOI: 10.1007/s00415-019-09248-6 Search in Google Scholar

43 Cellerino M, Boffa G, Lapucci C, Tazza F, Sbragia E, Mancuso E, et al. Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis. Neurotherapeutics. 2021;18(4):2579-2588. DOI: 10.1007/s13311-021-01104-8 Search in Google Scholar

44 Curran C, Vaitaitis G, Waid D, Volmer T, Alverez E, Wagner DH. Ocrevus Reduces TH40 Cells, a Biomarker of Systemic Inflammation, in Relapsing Multiple Sclerosis (RMS) and in Progressive Multiple Sclerosis (PMS). J Neuroimmunol. 2023;374:578008. DOI: 10.1016/j.jneuroim.2022.578008 Search in Google Scholar

45 Mancinelli CR, Rossi N, Capra R. Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology. Ther Clin Risk Manag. 2021;17:765-776. DOI: 10.2147/TCRM.S282390 Search in Google Scholar

46 Mey GM, Mahajan KR, DeSilva TM. Neurodegeneration in Multiple Sclerosis. WIREs Mech Dis. 2023;15(1):e1583. DOI: 10.1002/wsbm.1583 Search in Google Scholar

47 Lassmann H. Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis. Front Immunol. 2019;10:3116. DOI: 10.3389/fimmu.2018.03116 Search in Google Scholar

48 Trapp BD, Nave K-A. Multiple sclerosis: an immune or neurodegenerative disorder? Ann Rev Neurosci. 2008;31:247-269. DOI: 10.1146/annurev.neuro.30.051606.094313 Search in Google Scholar

49 Mahad DH, Trapp BD, Lassmann H. Pathological Mechanisms in Progressive Multiple Sclerosis. Lancet Neurol. 2015;14(2):183-93. DOI: 10.1016/S1474-4422(14)70256-X Search in Google Scholar

50 Stadelmann C. Multiple sclerosis as a neurodegenerative disease: Pathology, mechanisms and therapeutic implications. Curr Opin Neurol. 2011;24(3):224-229. DOI: 10.1097/WCO.0b013e328346056f Search in Google Scholar